| Identification | Back Directory | [Name]
H-ARG-GLN-OH HYDROCHLORIDE SALT | [CAS]
2483-17-2 | [Synonyms]
H-Arg-Gln-OH
H-ARG-GLN-OH HCL
L-Glutamine, L-arginyl-
H-ARG-GLN-OH HYDROCHLORIDE SALT
(S)-5-Amino-2-((S)-2-amino-5-guanidinopentanamido)-5-oxopentanoic acid | [Molecular Formula]
C11H22N6O4 | [MDL Number]
MFCD06795767 | [MOL File]
2483-17-2.mol | [Molecular Weight]
302.33 |
| Hazard Information | Back Directory | [Uses]
Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy[1]. | [Definition]
ChEBI: Arg-Gln is a dipeptide formed from L-arginyl and L-glutamine residues. It has a role as a metabolite. | [in vivo]
Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) dramatically inhibits retinal neovascularization in the mouse oxygen-induced retinopathy (OIR) model[1]. | Animal Model: | C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model[1] | | Dosage: | 1.0, 2.5, or 5 g/kg per day | | Administration: | Intraperitoneal injection, twice daily | | Result: | Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day.
|
| [References]
[1] Neu J, et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3151-5. DOI:10.1167/iovs.05-1473 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|